| Popis: |
Adverse events associated with hematopoietic progenitor cell (HPC) product infusion are varied and depend on the type of product infused. Reported rates of reactions generally range from 20–30% of infusions. Reactions include: bacterial contamination, volume overload, allergic, febrile non-hemolytic, hemolytic, TRALI (transfusion-related acute lung injury) and reactions related to the infusion of dimethylsulfoxide (DMSO). Adverse reactions must be documented in the patient’s medical record and reported in accordance with a facility’s policies and applicable laws and regulations. The majority of the adverse events related to stem cell infusions are mild to moderate in severity and self-limited. |
